Literature DB >> 23321197

Kyphoplasty for the treatment of very severe osteoporotic vertebral compression fracture.

H T Zhang1, Z Y Sun, X Y Zhu, K W Chen, Z L Qian, H L Yang.   

Abstract

OBJECTIVE: A retrospective evaluation of the clinical outcome and technical feasibility of kyphoplasty for the treatment of very severe osteoporotic vertebral compression fracture (vsOVCF).
METHODS: Patients with vsOVCF were treated with kyphoplasty and followed-up for 1 year. Vertebral body height variation, kyphotic angle, back pain (visual analogue scale [VAS]) and Oswestry disability index (ODI) were evaluated preoperatively, postoperatively, 1 month, 3 months and 1 year after treatment.
RESULTS: In total, 35 patients (49 vertebrae) were treated with kyphoplasty. There were no cases of spinal or extraspinal injury, infection, bleeding, pulmonary embolism, epidural cement leakage, stroke or cardiac arrest as a result of treatment. There were significant postoperative improvements in all outcome measures (vertebral body height variation, kyphotic angle, VAS and ODI); these improvements were maintained during the follow-up period.
CONCLUSION: Kyphoplasty is an effective and minimally invasive procedure for the treatment of vsOVCF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321197     DOI: 10.1177/030006051204000638

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  The Treatment Evaluation for Osteoporotic Kummell Disease by Modified Posterior Vertebral Column Resection: Minimum of One-Year Follow-Up.

Authors:  Da-Long Yang; Si-Dong Yang; Qian Chen; Yong Shen; Wen-Yuan Ding
Journal:  Med Sci Monit       Date:  2017-02-02

2.  Role of percutaneous vertebroplasty with high-viscosity cement in the treatment of severe osteoporotic vertebral compression fractures.

Authors:  Kunpeng Li; Changbin Ji; Dawei Luo; Wen Zhang; Hongyong Feng; Keshi Yang; Hui Xu
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.